{
  "lastUpdated": "2025-01-20T00:00:00Z",
  "totalSpend": 164000000,
  "dataSource": "ECRI Benchmarking + Surgical Analysis 2024",
  "vendors": [
    {
      "id": "stryker",
      "name": "Stryker",
      "marketShare": 34.3,
      "annualSpend": 54159893,
      "savingsPotential10th": 3852337,
      "savingsPotentialLow": 10830000,
      "leverageScore": 7.1,
      "color": "#BA4896",
      "strengths": [
        "Largest market share (34.3%)",
        "Strong technology portfolio",
        "Well-established physician relationships"
      ],
      "weaknesses": [
        "Premium pricing strategy",
        "Limited flexibility on discounting"
      ],
      "negotiationLeverage": [
        "Wants to grow market share to 40%+",
        "Recently lost major contracts to Zimmer",
        "Q4 2024 earnings pressure"
      ]
    },
    {
      "id": "zimmer",
      "name": "Zimmer Biomet",
      "marketShare": 32.7,
      "annualSpend": 46706788,
      "savingsPotential10th": 4804543,
      "savingsPotentialLow": 13575351,
      "leverageScore": 10.3,
      "color": "#8B6BA8",
      "strengths": [
        "Highest savings potential ($4.8M at 10th percentile)",
        "Strong product portfolio post-ZimVie",
        "Eager for volume commitments"
      ],
      "weaknesses": [
        "Integration challenges from ZimVie spinoff",
        "Market share erosion to Stryker"
      ],
      "negotiationLeverage": [
        "ZimVie spinoff created organizational pressure",
        "Needs to stabilize market share post-spinoff",
        "Most aggressive on pricing to secure volume"
      ]
    },
    {
      "id": "jnj",
      "name": "J&J (DePuy Synthes)",
      "marketShare": 18.3,
      "annualSpend": 34629221,
      "savingsPotential10th": 3473424,
      "savingsPotentialLow": 10910556,
      "leverageScore": 10.0,
      "color": "#5C8DBA",
      "strengths": [
        "Strong revision portfolio",
        "Excellent clinical support"
      ],
      "weaknesses": [
        "J&J MedTech integration ongoing",
        "Mid-tier pricing with limited flexibility"
      ],
      "negotiationLeverage": [
        "J&J MedTech separation creating focus",
        "Integration of DePuy Synthes brands",
        "Moderate pricing pressure"
      ]
    },
    {
      "id": "smith",
      "name": "Smith & Nephew",
      "marketShare": 6.2,
      "annualSpend": 12029995,
      "savingsPotential10th": 1886208,
      "savingsPotentialLow": 4307720,
      "leverageScore": 15.7,
      "color": "#4EAECC",
      "strengths": [
        "Smaller player with pricing flexibility",
        "Good backup option for physicians",
        "Strong leverage score (15.7%)"
      ],
      "weaknesses": [
        "Limited market share",
        "Smaller product portfolio"
      ],
      "negotiationLeverage": [
        "Desperate for volume to remain viable",
        "Highest leverage score among majors",
        "Excellent tertiary/backup option"
      ]
    }
  ],
  "savingsScenarios": [
    {
      "name": "Conservative (ECRI 10th)",
      "totalSavings": 15412592,
      "percentage": 9.4,
      "description": "Realistic target based on peer health system performance",
      "confidence": "high"
    },
    {
      "name": "Aggressive (ECRI Lowest)",
      "totalSavings": 45698453,
      "percentage": 27.9,
      "description": "Best-in-class pricing - requires aggressive consolidation",
      "confidence": "medium"
    }
  ]
}
